share_log

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425：募资说明/企业合并公告
SEC announcement ·  04/12 09:27
Moomoo AI 已提取核心信息
SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a merger agreement with AutoMax Motors Ltd., an Israeli vehicle importer. The agreement stipulates that SciSparc will acquire 100% of AutoMax, establishing a new wholly-owned subsidiary that will merge with AutoMax, making it a wholly-owned subsidiary of SciSparc. Post-acquisition, SciSparc shareholders are expected to hold approximately 50.01% of the combined company, while AutoMax equity holders will hold around 49.99%, subject to adjustments. SciSparc has committed to having at least $4.25 million in net cash at closing. The acquisition is contingent upon regulatory approvals, Israeli court approvals, and shareholder approvals from both companies. The transaction aligns with SciSparc's June 2022 announcement to explore strategic transactions to maximize shareholder value. The company's ongoing pharmaceutical operations will continue post-acquisition. The merger agreement is subject to various approvals, including compliance with regulatory requirements and approvals from SciSparc and AutoMax shareholders.
SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a merger agreement with AutoMax Motors Ltd., an Israeli vehicle importer. The agreement stipulates that SciSparc will acquire 100% of AutoMax, establishing a new wholly-owned subsidiary that will merge with AutoMax, making it a wholly-owned subsidiary of SciSparc. Post-acquisition, SciSparc shareholders are expected to hold approximately 50.01% of the combined company, while AutoMax equity holders will hold around 49.99%, subject to adjustments. SciSparc has committed to having at least $4.25 million in net cash at closing. The acquisition is contingent upon regulatory approvals, Israeli court approvals, and shareholder approvals from both companies. The transaction aligns with SciSparc's June 2022 announcement to explore strategic transactions to maximize shareholder value. The company's ongoing pharmaceutical operations will continue post-acquisition. The merger agreement is subject to various approvals, including compliance with regulatory requirements and approvals from SciSparc and AutoMax shareholders.
临床阶段的制药公司ScisPARC Ltd. 已与以色列汽车进口商AutoMax Motors Ltd.签订了合并协议。该协议规定，ScisPARC将收购AutoMax100％的股份，成立一家新的全资子公司，该子公司将与AutoMax合并，使其成为ScisPARC的全资子公司。收购后，ScisPARC的股东预计将持有合并后公司约50.01％的股份，而AutoMax的股东将持有约49.99％的股份，视调整而定。ScisPARC已承诺在收盘时拥有至少425万美元的净现金。此次收购取决于监管部门的批准、以色列法院的批准以及两家公司的股东批准。该交易与ScisPARC于2022年6月宣布的探索战略交易以最大化股东价值的声明一致。该公司正在进行的制药业务将在收购后继续。合并协议需要获得各种批准，包括遵守监管要求以及ScisPARC和AutoMax股东的批准。
临床阶段的制药公司ScisPARC Ltd. 已与以色列汽车进口商AutoMax Motors Ltd.签订了合并协议。该协议规定，ScisPARC将收购AutoMax100％的股份，成立一家新的全资子公司，该子公司将与AutoMax合并，使其成为ScisPARC的全资子公司。收购后，ScisPARC的股东预计将持有合并后公司约50.01％的股份，而AutoMax的股东将持有约49.99％的股份，视调整而定。ScisPARC已承诺在收盘时拥有至少425万美元的净现金。此次收购取决于监管部门的批准、以色列法院的批准以及两家公司的股东批准。该交易与ScisPARC于2022年6月宣布的探索战略交易以最大化股东价值的声明一致。该公司正在进行的制药业务将在收购后继续。合并协议需要获得各种批准，包括遵守监管要求以及ScisPARC和AutoMax股东的批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息